Financial Times (May 12)
2014/ 05/ 13 by jd in Global News
There’s little obvious business sense to Pfizer’s proposed takeover of AstraZeneca. Strategically, there’s not much to be gained aside from effecting a change of tax domicile. “Pfizer’s dealmaking history is moreover a deeply dispiriting one…. Despite having spent some $240bn on three big acquisitions since 2000, its market capitalisation is just $185bn today. Meanwhile the Dow Jones index is more than 40 per cent higher.” AstraZeneca’s directors must proceed warily. This is about more than the potential short-term profit to existing shareholders.
Tags: Acquisitions, AstraZeneca, Dealmaking, Directors, Dow Jones, Market-cap, Pfizer, Profit, Shareholders, Short term, Strategy, Takeover, Tax domicile
